See more : Live Oak Crestview Climate Acquisition Corp. (LOCC) Income Statement Analysis – Financial Results
Complete financial analysis of Tango Therapeutics, Inc. (TNGX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tango Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- EQT Corporation (EQT) Income Statement Analysis – Financial Results
- Kingfisher Mining Limited (KFM.AX) Income Statement Analysis – Financial Results
- Zovio Inc (ZVOI) Income Statement Analysis – Financial Results
- Måsøval AS (MAS.OL) Income Statement Analysis – Financial Results
- Locust Walk Acquisition Corp. (LWAC) Income Statement Analysis – Financial Results
Tango Therapeutics, Inc. (TNGX)
About Tango Therapeutics, Inc.
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 36.53M | 24.86M | 37.04M | 7.66M | 24.65M |
| Cost of Revenue | 115.20M | 4.03M | 1.97M | 1.63M | 32.27M |
| Gross Profit | -78.67M | 20.83M | 35.08M | 6.03M | -7.63M |
| Gross Profit Ratio | -215.38% | 83.80% | 94.69% | 78.77% | -30.93% |
| Research & Development | 115.20M | 105.91M | 77.64M | 49.99M | 32.27M |
| General & Administrative | 35.50M | 30.03M | 17.60M | 9.87M | 7.54M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 35.50M | 30.03M | 17.60M | 9.87M | 7.54M |
| Other Expenses | 0.00 | 2.95M | 247.00K | 120.00K | 0.00 |
| Operating Expenses | 150.70M | 135.93M | 95.23M | 59.86M | 7.15M |
| Cost & Expenses | 150.70M | 135.93M | 95.23M | 59.86M | 39.43M |
| Interest Income | 6.62M | 1.46M | 495.00K | 108.00K | 684.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.42M | 4.03M | 1.97M | 1.63M | 643.00K |
| EBITDA | -111.76M | -109.46M | -57.29M | -51.48M | -14.52M |
| EBITDA Ratio | -305.96% | -446.79% | -157.09% | -672.44% | -58.90% |
| Operating Income | -114.17M | -111.07M | -58.19M | -52.20M | -15.16M |
| Operating Income Ratio | -312.57% | -446.79% | -157.09% | -681.82% | -61.51% |
| Total Other Income/Expenses | 12.56M | 2.95M | 247.00K | 228.00K | 1.07M |
| Income Before Tax | -101.61M | -108.12M | -57.94M | -51.97M | -14.10M |
| Income Before Tax Ratio | -278.18% | -434.92% | -156.43% | -678.84% | -57.18% |
| Income Tax Expense | 134.00K | 54.00K | 292.00K | -108.00K | 0.00 |
| Net Income | -101.74M | -108.18M | -58.24M | -51.86M | -14.10M |
| Net Income Ratio | -278.54% | -435.14% | -157.21% | -677.43% | -57.18% |
| EPS | -1.08 | -1.23 | -0.94 | -1.62 | -1.57 |
| EPS Diluted | -1.08 | -1.23 | -0.94 | -1.62 | -1.57 |
| Weighted Avg Shares Out | 94.57M | 87.82M | 62.11M | 31.93M | 8.99M |
| Weighted Avg Shares Out (Dil) | 94.57M | 87.82M | 62.11M | 31.93M | 8.99M |
Tango Therapeutics to Participate in Upcoming Investor Conferences
BOSTON, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of...
Tango Therapeutics: Upcoming Proof Of Concept Data Is A Major Catalyst
Tango Therapeutics' SPAC entry to the market and Gilead deal has put a large dollar figure besides its name. Tango has an upcoming proof of concept data readout that should validate its platform.
Tango Therapeutics: Behind The Recent Momentum
Shares of early clinical-stage biotech Tango Therapeutics, Inc. are down ~50% since going public in August 2021 – primarily victimized by a lack of catalysts and a tough market. However, the shares have rallied strongly over the past month.
Tango Therapeutics to Participate in Upcoming Investor Conferences
BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of...
Why Tango Therapeutics Shares Rose 39.7% This Week
The clinical-stage biotech company has two candidates in its drug pipeline.
Best Penny Stocks To Buy Now? 3 With Heavy Insider Trading In October
Best penny stocks to buy this week according to insiders. The post Best Penny Stocks To Buy Now?
Tango Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of...
Tango Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that members of the management team are scheduled to participate...
Tango Therapeutics' TNG908 IND For Cancer Study Gets Green Signal By FDA
The FDA has cleared Tango Therapeutics Inc's (NASDAQ: TNGX) Investigational New Drug (IND) application for its lead program, TNG908. TNG908 is a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 (PRMT5) designed to kill cancer cells with a methylthioadenosine phosphorylase (MTAP)...
Tango Therapeutics Announces Presentation of Preclinical Data on Lead Program and Discovery Platform in Five Abstracts Accepted at AACR-NCI-EORTC 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that five abstracts have been selected for presentation as virtual posters at the AACR-NCI-EORTC International Conference...
Source: https://incomestatements.info
Category: Stock Reports